First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers
Preliminary Phase 2 data in melanoma, renal cell carcinoma anticipated to be presented by mid-2024